Literature DB >> 3724407

Pathophysiological factors which limit the exercise capacity of the sick child.

O Bar-Or.   

Abstract

While deficient exercise performance of sick children results from hypoactivity and detraining, it can also be caused by specific pathophysiological factors. These can affect one or more components of physical fitness. A low maximal aerobic power will result from a low maximal stroke volume, as in aortic stenosis or cardiomyopathy; a low maximal heart rate, as in congenital complete heart block or intake of beta-blockers; a low O2 content of the arterial blood, as in anemia or advanced cystic fibrosis; and a high O2 content of mixed-venous blood, as in muscle atrophy or severe malnutrition. A high O2 cost of locomotion, as in advanced obesity or cerebral palsy, will cause the patient to exert at a high percentage of his maximal aerobic power and thus fatigue easily. A subnormal muscle strength, as in progressive muscular dystrophy or juvenile rheumatoid arthritis, is sometimes the primary factor that limits the walking ability or other daily functions. Recent data suggest that local muscle endurance, as assessed by the Wingate anaerobic test, is particularly deficient in some neuromuscular diseases. Examples are muscular dystrophies and spastic cerebral palsy. The ratio of peak anaerobic power to peak aerobic power seems lower in such patients than in able-bodied controls.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3724407     DOI: 10.1249/00005768-198606000-00004

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  13 in total

Review 1.  Cardiac rehabilitation programmes in children.

Authors:  R L Washington
Journal:  Sports Med       Date:  1992-09       Impact factor: 11.136

2.  Compromised Exercise Capacity and Mitochondrial Dysfunction in the Osteogenesis Imperfecta Murine (oim) Mouse Model.

Authors:  Victoria L Gremminger; Youngjae Jeong; Rory P Cunningham; Grace M Meers; R Scott Rector; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2019-06-13       Impact factor: 6.741

3.  Schistosoma mansoni Infection as a Predictor of Low Aerobic Capacity in Ugandan Children.

Authors:  Courtney Smith; Georgia McLachlan; Hajri Al Shehri; Moses Adriko; Moses Arinaitwe; Aaron Atuhaire; Edridah Muheki Tukahebwa; E James LaCourse; Michelle Stanton; J Russell Stothard; Amaya L Bustinduy
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

4.  Skeletal muscle expression of LDH and monocarboxylate transporters in growing rats submitted to protein malnutrition.

Authors:  Lionel F Jouaville; Nicole Fellmann; Jean Coudert; Eric Clottes
Journal:  Eur J Nutr       Date:  2006-07-17       Impact factor: 5.614

Review 5.  Evaluation by exercise testing of the child with cerebral palsy.

Authors:  V B Unnithan; C Clifford; O Bar-Or
Journal:  Sports Med       Date:  1998-10       Impact factor: 11.136

6.  Cardiopulmonary exercise testing in congenital heart disease: equipment and test protocols.

Authors:  T Takken; A C Blank; E H Hulzebos; M van Brussel; W G Groen; P J Helders
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

7.  Cardiopulmonary exercise testing in congenital heart disease: (contra)indications and interpretation.

Authors:  T Takken; A C Blank; E H Hulzebos; M van Brussel; W G Groen; P J Helders
Journal:  Neth Heart J       Date:  2009-10       Impact factor: 2.380

8.  Effectiveness of an upper extremity exercise device and text message reminders to exercise in adults with spina bifida: a pilot study.

Authors:  Theresa M Crytzer; Brad E Dicianno; Andrea D Fairman
Journal:  Assist Technol       Date:  2013

9.  Prevalance of obesity in children with cerebral palsy.

Authors:  Ankita Bansal; Shraddha Diwan; Jasmin Diwan; Neeta Vyas
Journal:  J Clin Diagn Res       Date:  2014-08-20

Review 10.  Muscle fatigue during high-intensity exercise in children.

Authors:  Sébastien Ratel; Pascale Duché; Craig A Williams
Journal:  Sports Med       Date:  2006       Impact factor: 11.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.